PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB - Free Report) in a research note released on Friday morning,Benzinga reports. The firm currently has a $21.00 target price on the stock.

Several other equities analysts also recently commented on the company. StockNews.com downgraded PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, November 9th. Alliance Global Partners raised PDS Biotechnology to a "strong-buy" rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

PDS Biotechnology Stock Down 10.7 %

NASDAQ PDSB traded down $0.24 during mid-day trading on Friday, reaching $2.01. The stock had a trading volume of 726,457 shares, compared to its average volume of 616,373. The stock has a market cap of $74.01 million, a PE ratio of -1.65 and a beta of 1.93. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. PDS Biotechnology has a 1 year low of $1.53 and a 1 year high of $6.85. The company has a fifty day moving average price of $3.21 and a 200 day moving average price of $3.26.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same period in the previous year, the business earned ($0.37) earnings per share. On average, research analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Tempus Wealth Planning LLC purchased a new position in shares of PDS Biotechnology in the 2nd quarter valued at $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in PDS Biotechnology in the second quarter valued at $115,000. Squarepoint Ops LLC acquired a new stake in PDS Biotechnology during the second quarter worth about $120,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at $146,000. Institutional investors own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.